TElmisartan in the management of abDominal aortic aneurYsm (TEDY)

替米沙坦治疗腹主动脉瘤 (TEDY)

• 批准号: nhmrc : 1022752
• 负责人: Dr Anna Ahimastos
• 金额: $ 77.91万
• 依托单位: James Cook University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/telmisartan-management-abdominal-aneurysm-tedy/110217
• 关键词: TElmisartan; management; abDominal; aortic; aneurYsm

Approximately 5% of men and 1% of women aged over 60 years develop weakening of the main abdominal artery. Currently the management of artery weakening is focused on surgery with no effective medications available. In this trial we will examine the value of a promising drug therapy. If proved effective this medication could reduce the requirement for surgery by controlling artery weakening at an early stage in its development.

大约5%的男性和1%的60岁以上的女性会出现腹主动脉的衰弱。目前，动脉变弱的治疗主要集中在手术治疗上，没有有效的药物可用。在这项试验中，我们将检验一种有前途的药物疗法的价值。如果证明有效，这种药物可以通过在动脉发育的早期阶段控制动脉变弱来减少对手术的要求。